Potential role of probiotics in reducing Clostridioides difficile virulence: Interference with quorum sensing systems.

Clostridioides difficile Gram positive bacteria Probiotics Quorum quenching Quorum sensing Quorum sensing inhibitors

Journal

Microbial pathogenesis
ISSN: 1096-1208
Titre abrégé: Microb Pathog
Pays: England
ID NLM: 8606191

Informations de publication

Date de publication:
Apr 2021
Historique:
received: 05 06 2020
revised: 05 02 2021
accepted: 08 02 2021
pubmed: 21 2 2021
medline: 22 6 2021
entrez: 20 2 2021
Statut: ppublish

Résumé

Opportunistic pathogenic bacteria may cause disease after the normally protective microbiome is disrupted (typically by antibiotic exposure). Clostridioides difficile is one such pathogen having a severe impact on healthcare facilities and increasing costs of medical care. The search for new therapeutic strategies that are not reliant on additional antibiotic exposures are currently being explored. One such strategy is to disrupt the production of C. difficile virulence factors by interfering with quorum sensing (QS) systems. QS has been well studied in other bacteria, but our understanding in C. difficile is not so well understood. Some probiotic strains or combinations of strains have been shown to be effective in the treatment or primary prevention of C. difficile infections and may possess multiple mechanisms of action. One mechanism of probiotics might be the inhibition of QS, but their role has not been clearly defined yet. A literature search was conducted using standard databases (PubMed, Google Scholar) from database inception to August 2020. The objective of this paper is to update our understanding of how QS leads to toxin production by C. difficile, which is important in pathogenesis, and how QS inhibitors or probiotics may disrupt this pathway. We found two main QS systems for C. difficile (Agr and Lux systems) that are involved in C. difficile pathogenesis by regulating toxin production, motility and adherence. Probiotics and other QS inhibitors targeting QS systems may represent important new directions of therapy and prevention of CDI.

Identifiants

pubmed: 33609647
pii: S0882-4010(21)00070-X
doi: 10.1016/j.micpath.2021.104798
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

104798

Informations de copyright

Copyright © 2021 Elsevier Ltd. All rights reserved.

Auteurs

Sathursha Gunaratnam (S)

Institut National de Recherche Scientifique-Armand-Frappier, Health and Biotechnology Centre, Laval, QC, Canada.

Mathieu Millette (M)

Institut National de Recherche Scientifique-Armand-Frappier, Health and Biotechnology Centre, Laval, QC, Canada; Bio-K +, a Kerry Company, Laval, QC, Canada.

Lynne V McFarland (LV)

Department of Medicinal Chemistry, University of Washington, Seattle, WA, USA.

Herbert L DuPont (HL)

University of Texas Health Science Center, School of Public Health, Department of Epidemiology, Human Genetics and Environmental Sciences, Center for Infectious Diseases, Houston, TX, USA; Kelsey Research Foundation, Houston, TX, USA.

Monique Lacroix (M)

Institut National de Recherche Scientifique-Armand-Frappier, Health and Biotechnology Centre, Laval, QC, Canada. Electronic address: monique.lacroix@inrs.ca.

Articles similaires

Biofilms Candida albicans Quorum Sensing Candida glabrata Menthol
Genome, Bacterial Virulence Phylogeny Genomics Plant Diseases
Female Biofilms Animals Lactobacillus Mice

Classifications MeSH